{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=33", "query": { "intervention": "cyclophosphamide", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 598, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=32&page_size=10" }, "source": "local", "last_synced_at": "2026-10-28T23:22:55.037Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05052528", "title": "Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2021-09-17", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-28T23:22:55.037Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052528" }, { "nct_id": "NCT04530565", "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Electrocardiography", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 348, "start_date": "2021-01-25", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-27T02:53:56.838Z", "location_count": 207, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04530565" }, { "nct_id": "NCT03984448", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Double-Expressor Lymphoma", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 363, "start_date": "2019-10-22", "completion_date": "2028-08-13", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-26T22:06:28.567Z", "location_count": 634, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984448" }, { "nct_id": "NCT02153580", "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "B-Cell Prolymphocytic Leukemia", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Post-Transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Hairy Cell Leukemia", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2014-10-14", "completion_date": "2027-08-11", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-26T13:20:36.188Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02153580" }, { "nct_id": "NCT01464606", "title": "International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pleuropulmonary Blastoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dactinomycin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospitals and Clinics of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 156, "start_date": "2009-12-22", "completion_date": "2035-12-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T15:16:25.933Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01464606" }, { "nct_id": "NCT02306161", "title": "Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Ewing Sarcoma", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Malignant Neoplasm in the Bone Marrow", "Metastatic Malignant Neoplasm in the Lung", "Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone", "Peripheral Primitive Neuroectodermal Tumor of Soft Tissues" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Ganitumab", "type": "BIOLOGICAL" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Therapeutic Surgical Procedure", "type": "PROCEDURE" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": 312, "start_date": "2014-12-12", "completion_date": "2027-09-16", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-24T08:51:26.294Z", "location_count": 298, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 203 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02306161" }, { "nct_id": "NCT02158091", "title": "A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IPI-145", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2014-06-27", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-23T00:37:47.182Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02158091" }, { "nct_id": "NCT00972478", "title": "Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ann Arbor Stage II Non-Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2010-11-15", "completion_date": "2027-03-06", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-24T07:44:25.617Z", "location_count": 190, "location_summary": "Mobile, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 132 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00972478" }, { "nct_id": "NCT00792948", "title": "Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Adult L1 Acute Lymphoblastic Leukemia", "Adult L2 Acute Lymphoblastic Leukemia", "Adult T Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 97, "start_date": "2009-09-01", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-26T21:01:45.785Z", "location_count": 157, "location_summary": "Tucson, Arizona • Duarte, California • Palo Alto, California + 114 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00792948" }, { "nct_id": "NCT06112379", "title": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1902, "start_date": "2023-11-14", "completion_date": "2032-09-23", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-27T19:45:20.285Z", "location_count": 58, "location_summary": "Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Prescott", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06112379" } ] }